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Coronary No-Reflow Following Percutaneous Intervention
Adam Levine,
1South

INTRODUCTION
• Primary percutaneous coronary
intervention (PPCI) is the gold standard of
treatment of ST segment elevation
myocardial infarction (STEMI).
• PPCI restores thrombolysis in myocardial
infarction flow 3 (TIMI 3) in over 90% of
patients [1].
• However, in rare instances, coronary
revascularization does not lead to
coronary reperfusion, instead there is a
further decrease of coronary blood flow.
• The cause of no-reflow can be classified
into four main pathogenetic components:
distal athero-thrombotic embolization,
ischemia-related and/or reperfusionrelated injury, and the susceptibility of
coronary microcirculation to injury.
• The purpose of this case report is to show
early and clear identification of the no reflow and follow its management. It can
occur in up to 10% of cases of primary PCI
and is associated with an increased 30
day mortality if not adequately treated
(32% vs. 2.8%, p<.0. 001) [2].

CASE REPORT
• A 76-yr-old female presented to the
emergency department with new-onset
substernal chest pain over 3 days.
• Her primary care physician initially
diagnosed her with GERD, but then her
chest pain acutely worsened and she
developed dyspnea on exertion as well
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• PMH: hypertension, hyperlipidemia, type
2 diabetes mellitus, Raynaud’s disease,
rheumatoid arthritis, degenerative joint
disease, and Sjogren’s disease.
• Vital Signs: blood pressure 52/44 , pulse
of 122, respiratory rate of 20,
temperature 36.8 C, and SpO2 100% on
room air.
• Physical Exam: findings were
unremarkable.
• EKG: On admission showed an
anterolateral wall ST-elevation myocardial
infarction (STEMI) for which she had to be
taken emergently for left heart
catheterization.
• Hospital Course: During PCI, she had a
drug-eluting stent (DES) placed to 100%
lesion of the proximal LAD but there was
no re-flow following placement.
• The patient became bradycardic,
hypotensive, and agonal; within a few
minutes she had two episodes of cardiac
arrest with return of spontaneous
circulation (ROSC) achieved with CPR,
epinephrine, and atropine.
• She then had to be sedated and
intubated, started on a norepinephrine
bitartrate drip for hypotension.
• For her no re-flow after stenting and
coronary vasospasm, she was treated
with intracardiac nicardipine, adenosine,
and eptifibatide.
• There was subsequent placement of IABP

which was upgraded to a right femoral artery
Impella®. Unfortunately, there was
subsequent development of Impella® site
bleeding and a right groin hematoma.
• On Day 2 of hospitalization, the patient’s
MAP dropped below 65 with increasing
pressor requirements. CBC showed Hb 5.5
following 8 units of pRBC, which was
concerning for acute blood loss, and
patient’s right groin hematoma was
expanding to the abdominal wall and
down her right thigh.
• At this point, the patient was urgently
transferred to University of Pennsylvania
for further evaluation.

IMAGING

no-reflow phenomenon characterized by
evidence of slow-flow in the affected vessel
(TIMI flow equal to or less than 2) and lack
of contrast uptake “blush” by the
subtended myocardium, leading to a
potential dissociation between coronary
revascularization and myocardial perfusion
in STEMI [3]. ”
• There are several treatment options for
no re-flow, although it is not known
which treatment is best
• Current medical treatment options are
the following: injection of adenosine
(dilator of arteries and arterioles),
nitroprusside sodium (relaxes arteries
and veins), and verapamil (smooth
muscle dilator) [2, 3].

CONCLUSION

•
•
•

Figure 1: Acute 100%
occlusion of LAD
Figure 2: Drug eluting stent
placed
Figure 3: Intracoronary
infusion of nicardipine,
adenosine, and eptifibatide,
with minimal improvement.
TIMI Score 1-2

DISCUSSION
• For our patient, PCI did not lead to the
usual and expected restoration of
coronary blood flow.
• She had evidence of angiographic

• The prognosis and presentation of patients
with coronary no re-flow can vary.
• For the last few decades, treatment of no
re-flow has been mostly
pharmacotherapy-based, without much
success. There is a poor prognostic effect
of no-reflow causing an increase in fiveyear mortality from 9.5 to 18.2 percent
• This case depicts why it is important to
recognize coronary no re-flow early and to
continue exploring treatment options.
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